Examining the clinical significance of microvascular inflammation after kidney transplantation

Medical Xpress / American Society of Nephrology / ASN Kidney Week 2024 ^ | Oct. 24, 2024 | Aurélie Sannier et al

[ConservativeMind]

Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant.

Kidney transplant rejection continues to threaten the long-term success of kidney transplants, with microvascular inflammation (inflammation within capillaries) playing a pivotal role in graft failure. Due to its complex nature, this inflammation poses a major challenge in clinical practice.

In response, the international Banff classification—the global standard for diagnosing transplant rejection—has redefined antibody-mediated rejection diagnostics by introducing two new categories of microvascular inflammation: mild microvascular inflammation with probable antibody-mediated rejection and microvascular inflammation in the absence of antibody-mediated responses.

In a landmark study analyzing more than 16,000 biopsies from almost 7,000 kidney transplant recipients, researchers found that many cases initially considered as non-rejection were reclassified into the newly defined categories of microvascular inflammation. Importantly, reclassified patients with microvascular inflammation in the absence of antibody-mediated responses displayed an increased risk of graft failure compared with those without signs of rejection, underscoring the importance of this new classification.

"Recognizing these phenotypes could improve risk stratification and support more personalized management for kidney transplant patients," explains first author, Aurélie Sannier, pathologist and researcher at the Paris Institute for Transplantation and Organ Regeneration. "We encourage large studies in other organ transplants where microvascular inflammation is also a critical feature of antibody-mediated rejection."

[ConservativeMind]

This study appears to describe kidney transplant problems previously not understood, to being caused by microvascular inflammation. Although there were two categories identified, either from antibody issues or not, it still points to continued microvascular inflammation.

There is another study that I had looked at with a supplement that helps with reducing kidney dialysis microvascular inflammation, but specific to non-transplant situations. It has a special form of fucoidan in it. My wife and I have been taking it daily since January or February. We credit it with part of our blood pressure drop, as it is shown to open up clogged capillaries and growing capillaries, while protecting the endothelial layer across all vessels. I will post a list of its studies, including two referencing kidney inflammation reduction approaches with fucoidan, next.

[ConservativeMind]

Endocalyx Pro (and Fucoidan) Studies

Kidney and other studies:
https://microvascular.com/endocalyx-pro-studies/

[ConservativeMind]

The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.

[ConservativeMind]

Another supplement we take is called “Arterosil HP,” and it uses a different seaweed component, rhamnan sulfate. It has other studies behind it, and it can help lower blood pressure and reduce arterial plaque buildup.

[ConservativeMind]

More on this kidney issue, here:

https://medicalxpress.com/news/2024-10-refines-kidney-transplant.html